Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

Main navigation

Global One Health LLC helps conduct causality assessment of AEFI

The Ohio State Global One Health LLC supported the Ethiopian Food and Drug Authority (EFDA) to undertake a causality assessment of adverse events following COVID-19 vaccines reported to the pharmacovigilance system. Experts from the national pharmacovigilance advisory committee, the EFDA pharmacovigilance team and 26 clinicians conducted the assessment.

The committee selected 13 adverse events following immunization (AEFI) to assess for causality. As part of this session, the committee also reviewed six AEFIs reported following the Oral (OPV) Novel Type 2 (NOPV2) vaccine. Causal associations between the vaccines and the reported vaccine reactions were assessed and determined.

Based on the assessment result, the team devised recommendations that support the system to take appropriate regulatory actions and corrective measures to ensure a safe immunization program in Ethiopia.